EnteroMedics' obesity device fails to measure up in US trial – again
This article was originally published in Clinica
Executive Summary
EnteroMedics' share price has plunged 56% after reporting that its Maestro weight-loss device failed, for the second time, to meet its primary endpoint in a pivotal trial. However, the firm still plans to file a premarket approval (PMA) application with the US FDA in the second quarter. It is taking solace in the fact there was significant weight loss in patients treated with the device compared with a control group receiving sham therapy – although the effects was not as large as EnteroMedics had hoped for.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.